{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:59:58Z","timestamp":1781092798251,"version":"3.54.1"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA260581-01"],"award-info":[{"award-number":["U54CA260581-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA260581-01"],"award-info":[{"award-number":["U54CA260581-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA260581-01"],"award-info":[{"award-number":["U54CA260581-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA260581-01"],"award-info":[{"award-number":["U54CA260581-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA260581-01"],"award-info":[{"award-number":["U54CA260581-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA260581-01"],"award-info":[{"award-number":["U54CA260581-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA260581-01"],"award-info":[{"award-number":["U54CA260581-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA260581-01"],"award-info":[{"award-number":["U54CA260581-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA260581-01"],"award-info":[{"award-number":["U54CA260581-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA260581-01"],"award-info":[{"award-number":["U54CA260581-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA260581-01"],"award-info":[{"award-number":["U54CA260581-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA260581-01"],"award-info":[{"award-number":["U54CA260581-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA260581-01"],"award-info":[{"award-number":["U54CA260581-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA260581-01"],"award-info":[{"award-number":["U54CA260581-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA260581-01"],"award-info":[{"award-number":["U54CA260581-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA260581-01"],"award-info":[{"award-number":["U54CA260581-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA260581-01"],"award-info":[{"award-number":["U54CA260581-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA260581-01"],"award-info":[{"award-number":["U54CA260581-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA260581-01"],"award-info":[{"award-number":["U54CA260581-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-46564-0","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:37:08Z","timestamp":1776422228000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antiretroviral therapy interferes with pseudovirus neutralization assays while Gag-specific T-cells influence mRNA vaccine outcomes in HIV patients"],"prefix":"10.1038","volume":"16","author":[{"given":"Sean M.","family":"Litwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivy V.","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangyi","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Sabino-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie E.","family":"Murrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan C.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sruti","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra H.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley R.","family":"Smira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik L.","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariza","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly A.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Scheuermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Zwezdaryk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Maness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy B.","family":"Karger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Schieffelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwyn M.","family":"Gunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal Y.","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth B.","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"46564_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.35","volume":"1","author":"SG Deeks","year":"2015","unstructured":"Deeks, S. G., Overbaugh, J., Phillips, A. & Buchbinder, S. HIV infection. Nat. Rev. Dis. Primers. 1, 15035. https:\/\/doi.org\/10.1038\/nrdp.2015.35 (2015).","journal-title":"Nat. Rev. Dis. Primers."},{"key":"46564_CR2","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1016\/S2352-3018(21)00070-9","volume":"8","author":"J Ambrosioni","year":"2021","unstructured":"Ambrosioni, J. et al. Overview of SARS-CoV-2 infection in adults living with HIV. Lancet HIV 8, e294\u2013e305. https:\/\/doi.org\/10.1016\/S2352-3018(21)00070-9 (2021).","journal-title":"Lancet HIV"},{"key":"46564_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18073554","author":"KW Lee","year":"2021","unstructured":"Lee, K. W., Yap, S. F., Ngeow, Y. F. & Lye, M. S. COVID-19 in people living with HIV: A systematic review and meta-analysis. Int. J. Environ. Res. Public Health https:\/\/doi.org\/10.3390\/ijerph18073554 (2021).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"46564_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26137-7","volume":"12","author":"A Alrubayyi","year":"2021","unstructured":"Alrubayyi, A. et al. Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV. Nat. Commun. 12, 5839. https:\/\/doi.org\/10.1038\/s41467-021-26137-7 (2021).","journal-title":"Nat. Commun."},{"key":"46564_CR5","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1016\/S2352-3018(22)00097-2","volume":"9","author":"S Bertagnolio","year":"2022","unstructured":"Bertagnolio, S. et al. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: Analysis of data from the WHO Global Clinical Platform of COVID-19. Lancet. HIV. 9, e486\u2013e495. https:\/\/doi.org\/10.1016\/S2352-3018(22)00097-2 (2022).","journal-title":"Lancet. HIV."},{"key":"46564_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11904-022-00618-w","volume":"19","author":"MA Spinelli","year":"2022","unstructured":"Spinelli, M. A., Jones, B. L. H. & Gandhi, M. COVID-19 outcomes and risk factors among people living with HIV. Curr. HIV\/AIDS. Rep. 19, 425\u2013432. https:\/\/doi.org\/10.1007\/s11904-022-00618-w (2022).","journal-title":"Curr. HIV\/AIDS. Rep."},{"key":"46564_CR7","doi-asserted-by":"publisher","first-page":"e1964","DOI":"10.1093\/cid\/ciaa1339","volume":"73","author":"D Dandachi","year":"2021","unstructured":"Dandachi, D. et al. Characteristics, comorbidities, and outcomes in a multicenter registry of patients with Human Immunodeficiency Virus and Coronavirus Disease 2019. Clin. Infect. Dis. 73, e1964\u2013e1972. https:\/\/doi.org\/10.1093\/cid\/ciaa1339 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"46564_CR8","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1086\/598193","volume":"48","author":"J Evison","year":"2009","unstructured":"Evison, J. et al. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin. Infect. Dis. 48, 1402\u20131412. https:\/\/doi.org\/10.1086\/598193 (2009).","journal-title":"Clin. Infect. Dis."},{"key":"46564_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/QCO.0b013e328334fec4","volume":"23","author":"AM Geretti","year":"2010","unstructured":"Geretti, A. M. & Doyle, T. Immunization for HIV-positive individuals. Curr. Opin. Infect. Dis. 23, 32\u201338. https:\/\/doi.org\/10.1097\/QCO.0b013e328334fec4 (2010).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"46564_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/cid\/cit816","volume":"58","author":"LG Rubin","year":"2014","unstructured":"Rubin, L. G. et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58, 309\u2013318. https:\/\/doi.org\/10.1093\/cid\/cit816 (2014).","journal-title":"Clin Infect Dis"},{"key":"46564_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.yapd.2012.04.017","volume":"59","author":"MA Miller","year":"2012","unstructured":"Miller, M. A. & Rathore, M. H. Immunization in special populations. Adv. Pediatr. 59, 95\u2013136. https:\/\/doi.org\/10.1016\/j.yapd.2012.04.017 (2012).","journal-title":"Adv. Pediatr."},{"key":"46564_CR12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41423-023-01087-w","volume":"21","author":"MA Hoft","year":"2024","unstructured":"Hoft, M. A., Burgers, W. A. & Riou, C. The immune response to SARS-CoV-2 in people with HIV. Cell. Mol. Immunol. 21, 184\u2013196. https:\/\/doi.org\/10.1038\/s41423-023-01087-w (2024).","journal-title":"Cell. Mol. Immunol."},{"key":"46564_CR13","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1080\/22221751.2022.2059401","volume":"11","author":"L Ao","year":"2022","unstructured":"Ao, L. et al. Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV. Emerg. Microbes Infect. 11, 1126\u20131134. https:\/\/doi.org\/10.1080\/22221751.2022.2059401 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"46564_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/v14030651","author":"KG Schmidt","year":"2022","unstructured":"Schmidt, K. G. et al. Characterization of serum and mucosal SARS-CoV-2-antibodies in HIV-1-infected subjects after BNT162b2 mRNA vaccination or SARS-CoV-2 infection. Viruses https:\/\/doi.org\/10.3390\/v14030651 (2022).","journal-title":"Viruses"},{"key":"46564_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105862","volume":"26","author":"E Touizer","year":"2023","unstructured":"Touizer, E. et al. Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles. iScience 26, 105862. https:\/\/doi.org\/10.1016\/j.isci.2022.105862 (2023).","journal-title":"iScience"},{"key":"46564_CR16","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/hiv.13202","volume":"23","author":"N Jedicke","year":"2022","unstructured":"Jedicke, N. et al. Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy. HIV Med. 23, 558\u2013563. https:\/\/doi.org\/10.1111\/hiv.13202 (2022).","journal-title":"HIV Med."},{"key":"46564_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314988","author":"E Tortellini","year":"2022","unstructured":"Tortellini, E. et al. Quality of T-cell response to SARS-CoV-2 mRNA vaccine in ART-treated PLWH. Int J Mol Sci https:\/\/doi.org\/10.3390\/ijms232314988 (2022).","journal-title":"Int J Mol Sci"},{"key":"46564_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100287","volume":"13","author":"A Lombardi","year":"2022","unstructured":"Lombardi, A. et al. Anti-spike antibodies and neutralising antibody activity in people living with HIV vaccinated with COVID-19 mRNA-1273 vaccine: A prospective single-centre cohort study. Lancet Reg Health Eur. 13, 100287. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100287 (2022).","journal-title":"Lancet Reg Health Eur."},{"key":"46564_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijid.2023.11.029","volume":"139","author":"X Yang","year":"2024","unstructured":"Yang, X. et al. COVID-19 breakthrough infections among people living with and without HIV: A statewide cohort analysis. Int. J. Infect. Dis. 139, 21\u201327. https:\/\/doi.org\/10.1016\/j.ijid.2023.11.029 (2024).","journal-title":"Int. J. Infect. Dis."},{"key":"46564_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41541-024-00972-3","volume":"9","author":"A Alirezaylavasani","year":"2024","unstructured":"Alirezaylavasani, A. et al. Vaccine responses and hybrid immunity in people living with HIV after SARS-CoV-2 breakthrough infections. NPJ Vaccines 9, 185. https:\/\/doi.org\/10.1038\/s41541-024-00972-3 (2024).","journal-title":"NPJ Vaccines"},{"key":"46564_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1231276","volume":"14","author":"BM Motsoeneng","year":"2023","unstructured":"Motsoeneng, B. M. et al. Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination. Front. Immunol. 14, 1231276. https:\/\/doi.org\/10.3389\/fimmu.2023.1231276 (2023).","journal-title":"Front. Immunol."},{"key":"46564_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/v15020575","author":"Y Alexandrova","year":"2023","unstructured":"Alexandrova, Y. et al. SARS-CoV-2 vaccine-induced T-cell response after three doses in people living with HIV on antiretroviral therapy compared to seronegative controls (CTN 328 COVAXHIV Study). Viruses https:\/\/doi.org\/10.3390\/v15020575 (2023).","journal-title":"Viruses"},{"key":"46564_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.15934","volume":"5","author":"SB Coburn","year":"2022","unstructured":"Coburn, S. B. et al. Analysis of postvaccination breakthrough COVID-19 infections among adults with HIV in the United States. JAMA Netw Open 5, e2215934. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.15934 (2022).","journal-title":"JAMA Netw Open"},{"key":"46564_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10122129","author":"JH Park","year":"2022","unstructured":"Park, J. H., Chung, H., Kim, M. C., Choi, S. H. & Chung, J. W. Immune responses against the omicron variant of SARS-CoV-2 after a third dose of COVID-19 vaccine in patients living with human immunodeficiency virus (PLWH): Comparison with healthcare workers. Vaccines (Basel) https:\/\/doi.org\/10.3390\/vaccines10122129 (2022).","journal-title":"Vaccines (Basel)"},{"key":"46564_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/v15122427","author":"MM Qu","year":"2023","unstructured":"Qu, M. M. et al. Effect of SARS-CoV-2 breakthrough infection on HIV reservoirs and T-cell immune recovery in 3-dose vaccinated people living with HIV. Viruses https:\/\/doi.org\/10.3390\/v15122427 (2023).","journal-title":"Viruses"},{"key":"46564_CR26","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/COH.0b013e32833647a8","volume":"5","author":"A Elhed","year":"2010","unstructured":"Elhed, A. & Unutmaz, D. Th17 cells and HIV infection. Curr. Opin. HIV AIDS. 5, 146\u2013150. https:\/\/doi.org\/10.1097\/COH.0b013e32833647a8 (2010).","journal-title":"Curr. Opin. HIV AIDS."},{"key":"46564_CR27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/imr.12085","volume":"255","author":"T Veiga-Parga","year":"2013","unstructured":"Veiga-Parga, T., Sehrawat, S. & Rouse, B. T. Role of regulatory T cells during virus infection. Immunol. Rev. 255, 182\u2013196. https:\/\/doi.org\/10.1111\/imr.12085 (2013).","journal-title":"Immunol. Rev."},{"key":"46564_CR28","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.jaci.2009.09.017","volume":"125","author":"FA Bonilla","year":"2010","unstructured":"Bonilla, F. A. & Oettgen, H. C. Adaptive immunity. J. Allergy Clin. Immunol. 125, S33-40. https:\/\/doi.org\/10.1016\/j.jaci.2009.09.017 (2010).","journal-title":"J. Allergy Clin. Immunol."},{"key":"46564_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nri2524","volume":"9","author":"S Moir","year":"2009","unstructured":"Moir, S. & Fauci, A. S. B cells in HIV infection and disease. Nat. Rev. Immunol. 9, 235\u2013245. https:\/\/doi.org\/10.1038\/nri2524 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"46564_CR30","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nm.4113","volume":"22","author":"R Banga","year":"2016","unstructured":"Banga, R. et al. PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat. Med. 22, 754\u2013761. https:\/\/doi.org\/10.1038\/nm.4113 (2016).","journal-title":"Nat. Med."},{"key":"46564_CR31","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/ni1302","volume":"7","author":"X Qiao","year":"2006","unstructured":"Qiao, X. et al. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat. Immunol. 7, 302\u2013310. https:\/\/doi.org\/10.1038\/ni1302 (2006).","journal-title":"Nat. Immunol."},{"key":"46564_CR32","first-page":"556","volume":"86","author":"SP Sweet","year":"1995","unstructured":"Sweet, S. P., Rahman, D. & Challacombe, S. J. IgA subclasses in HIV disease: Dichotomy between raised levels in serum and decreased secretion rates in saliva. Immunology 86, 556\u2013559 (1995).","journal-title":"Immunology"},{"key":"46564_CR33","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/0091-6749(88)90132-7","volume":"82","author":"JA Fling","year":"1988","unstructured":"Fling, J. A., Fischer, J. R. Jr., Boswell, R. N. & Reid, M. J. The relationship of serum IgA concentration to human immunodeficiency virus (HIV) infection: A cross-sectional study of HIV-seropositive individuals detected by screening in the United States Air Force. J. Allergy Clin. Immunol. 82, 965\u2013970. https:\/\/doi.org\/10.1016\/0091-6749(88)90132-7 (1988).","journal-title":"J. Allergy Clin. Immunol."},{"key":"46564_CR34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/BF00920796","volume":"12","author":"C Vincent","year":"1992","unstructured":"Vincent, C. et al. Secretory immunoglobulins in serum from human immunodeficiency virus (HIV)-infected patients. J. Clin. Immunol. 12, 381\u2013388. https:\/\/doi.org\/10.1007\/BF00920796 (1992).","journal-title":"J. Clin. Immunol."},{"key":"46564_CR35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.0300-9475.2004.01376.x","volume":"59","author":"ES Lugada","year":"2004","unstructured":"Lugada, E. S. et al. Immunoglobulin levels amongst persons with and without human immunodeficiency virus type 1 infection in Uganda and Norway. Scand. J. Immunol. 59, 203\u2013208. https:\/\/doi.org\/10.1111\/j.0300-9475.2004.01376.x (2004).","journal-title":"Scand. J. Immunol."},{"key":"46564_CR36","unstructured":"Louisiana Department of Health (ed) 1\u201311 (2022)."},{"key":"46564_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-33320-x","volume":"13","author":"AA Prather","year":"2023","unstructured":"Prather, A. A. et al. Predictors of long-term neutralizing antibody titers following COVID-19 vaccination by three vaccine types: The BOOST study. Sci. Rep. 13, 6505. https:\/\/doi.org\/10.1038\/s41598-023-33320-x (2023).","journal-title":"Sci. Rep."},{"key":"46564_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.70039","volume":"12","author":"G Sabino-Santos","year":"2024","unstructured":"Sabino-Santos, G. et al. Post-COVID immunity in patients with solid tumor or hematological malignancies treated with SARS-CoV-2 monoclonal antibodies. Immun. Inflamm. Dis. 12, e70039. https:\/\/doi.org\/10.1002\/iid3.70039 (2024).","journal-title":"Immun. Inflamm. Dis."},{"key":"46564_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248348","volume":"16","author":"SN Neerukonda","year":"2021","unstructured":"Neerukonda, S. N. et al. Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. PLoS ONE 16, e0248348. https:\/\/doi.org\/10.1371\/journal.pone.0248348 (2021).","journal-title":"PLoS ONE"},{"key":"46564_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03154-6","volume":"11","author":"Y Huang","year":"2021","unstructured":"Huang, Y. et al. Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. Sci. Rep. 11, 23921. https:\/\/doi.org\/10.1038\/s41598-021-03154-6 (2021).","journal-title":"Sci. Rep."},{"key":"46564_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2024.100236","volume":"3","author":"S Tong","year":"2024","unstructured":"Tong, S. et al. Altered COVID-19 immunity in children with asthma by atopic status. J. Allergy Clin. Immunol. Glob. 3, 100236. https:\/\/doi.org\/10.1016\/j.jacig.2024.100236 (2024).","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"46564_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28543","volume":"95","author":"E De La Torre-Tarazona","year":"2023","unstructured":"De La Torre-Tarazona, E. et al. Treatment with integrase inhibitors alters SARS-CoV-2 neutralization levels measured with HIV-based pseudotypes in people living with HIV. J. Med. Virol. 95, e28543. https:\/\/doi.org\/10.1002\/jmv.28543 (2023).","journal-title":"J. Med. Virol."},{"key":"46564_CR43","doi-asserted-by":"publisher","unstructured":"Alrubayyi, A. et al. Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV. bioRxiv (2021). https:\/\/doi.org\/10.1101\/2021.02.15.431215","DOI":"10.1101\/2021.02.15.431215"},{"key":"46564_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009958","volume":"17","author":"N Mishra","year":"2021","unstructured":"Mishra, N. et al. Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma. PLoS Pathog. 17, e1009958. https:\/\/doi.org\/10.1371\/journal.ppat.1009958 (2021).","journal-title":"PLoS Pathog."},{"key":"46564_CR45","doi-asserted-by":"publisher","first-page":"5468","DOI":"10.1128\/JVI.03403-12","volume":"87","author":"ME Ackerman","year":"2013","unstructured":"Ackerman, M. E. et al. Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcgammaR2a and FcgammaR2b. J Virol 87, 5468\u20135476. https:\/\/doi.org\/10.1128\/JVI.03403-12 (2013).","journal-title":"J Virol"},{"key":"46564_CR46","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1172\/JCI126391","volume":"129","author":"SD Neidich","year":"2019","unstructured":"Neidich, S. D. et al. Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. J. Clin. Invest. 129, 4838\u20134849. https:\/\/doi.org\/10.1172\/JCI126391 (2019).","journal-title":"J. Clin. Invest."},{"key":"46564_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01062","volume":"10","author":"M Tuen","year":"2019","unstructured":"Tuen, M. et al. Immune correlates of disease progression in linked HIV-1 infection. Front. Immunol. 10, 1062. https:\/\/doi.org\/10.3389\/fimmu.2019.01062 (2019).","journal-title":"Front. Immunol."},{"key":"46564_CR48","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41577-022-00813-1","volume":"23","author":"A Zhang","year":"2023","unstructured":"Zhang, A. et al. Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nat. Rev. Immunol. 23, 381\u2013396. https:\/\/doi.org\/10.1038\/s41577-022-00813-1 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"46564_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2019.07.002","volume":"473","author":"S Fischinger","year":"2019","unstructured":"Fischinger, S. et al. A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation. J. Immunol. Methods. 473, 112630. https:\/\/doi.org\/10.1016\/j.jim.2019.07.002 (2019).","journal-title":"J. Immunol. Methods."},{"key":"46564_CR50","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.immuni.2021.08.001","volume":"54","author":"MM Painter","year":"2021","unstructured":"Painter, M. M. et al. Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity 54, 2133\u20132142. https:\/\/doi.org\/10.1016\/j.immuni.2021.08.001 (2021).","journal-title":"Immunity"},{"key":"46564_CR51","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","volume":"183","author":"T Sekine","year":"2020","unstructured":"Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183, 158-168 e114. https:\/\/doi.org\/10.1016\/j.cell.2020.08.017 (2020).","journal-title":"Cell"},{"key":"46564_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24377-1","volume":"12","author":"JH Jung","year":"2021","unstructured":"Jung, J. H. et al. SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells. Nat. Commun. 12, 4043. https:\/\/doi.org\/10.1038\/s41467-021-24377-1 (2021).","journal-title":"Nat. Commun."},{"key":"46564_CR53","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489-1501 e1415. https:\/\/doi.org\/10.1016\/j.cell.2020.05.015 (2020).","journal-title":"Cell"},{"key":"46564_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl9105","volume":"6","author":"MML Poon","year":"2021","unstructured":"Poon, M. M. L. et al. SARS-CoV-2 infection generates tissue-localized immunological memory in humans. Sci. Immunol. 6, eabl9105. https:\/\/doi.org\/10.1126\/sciimmunol.abl9105 (2021).","journal-title":"Sci. Immunol."},{"key":"46564_CR55","doi-asserted-by":"publisher","first-page":"7357","DOI":"10.1128\/JVI.00728-14","volume":"88","author":"M Schieffer","year":"2014","unstructured":"Schieffer, M. et al. Induction of Gag-specific CD4 T cell responses during acute HIV infection is associated with improved viral control. J. Virol. 88, 7357\u20137366. https:\/\/doi.org\/10.1128\/JVI.00728-14 (2014).","journal-title":"J. Virol."},{"key":"46564_CR56","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/COH.0000000000000086","volume":"9","author":"JC Mudd","year":"2014","unstructured":"Mudd, J. C. & Lederman, M. M. CD8 T cell persistence in treated HIV infection. Curr. Opin. HIV AIDS. 9, 500\u2013505. https:\/\/doi.org\/10.1097\/COH.0000000000000086 (2014).","journal-title":"Curr. Opin. HIV AIDS."},{"key":"46564_CR57","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41577-020-0274-9","volume":"20","author":"DR Collins","year":"2020","unstructured":"Collins, D. R., Gaiha, G. D. & Walker, B. D. CD8(+) T cells in HIV control, cure and prevention. Nat. Rev. Immunol. 20, 471\u2013482. https:\/\/doi.org\/10.1038\/s41577-020-0274-9 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"46564_CR58","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1093\/infdis\/jiu669","volume":"211","author":"M Helleberg","year":"2015","unstructured":"Helleberg, M. et al. Course and clinical significance of CD8+ T-cell counts in a large cohort of HIV-infected individuals. J. Infect. Dis. 211, 1726\u20131734. https:\/\/doi.org\/10.1093\/infdis\/jiu669 (2015).","journal-title":"J. Infect. Dis."},{"key":"46564_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26020862","author":"JB De Sanctis","year":"2025","unstructured":"De Sanctis, J. B., Balda Noria, G. & Garcia, A. H. Exploring how adipose tissue, obesity, and gender influence the immune response to vaccines: A comprehensive narrative review. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms26020862 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"46564_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1433531","volume":"15","author":"S Jang","year":"2024","unstructured":"Jang, S., Hong, W. & Moon, Y. Obesity-compromised immunity in post-COVID-19 condition: A critical control point of chronicity. Front. Immunol. 15, 1433531. https:\/\/doi.org\/10.3389\/fimmu.2024.1433531 (2024).","journal-title":"Front. Immunol."},{"key":"46564_CR61","doi-asserted-by":"publisher","first-page":"5625","DOI":"10.4049\/jimmunol.1501524","volume":"195","author":"R Cubas","year":"2015","unstructured":"Cubas, R. et al. Reversible reprogramming of circulating memory T follicular helper cell function during chronic HIV infection. J. Immunol. 195, 5625\u20135636. https:\/\/doi.org\/10.4049\/jimmunol.1501524 (2015).","journal-title":"J. Immunol."},{"key":"46564_CR62","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1172\/JCI64314","volume":"122","author":"M Lindqvist","year":"2012","unstructured":"Lindqvist, M. et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J. Clin. Invest. 122, 3271\u20133280. https:\/\/doi.org\/10.1172\/JCI64314 (2012).","journal-title":"J. Clin. Invest."},{"key":"46564_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1184362","volume":"14","author":"D Cantoni","year":"2023","unstructured":"Cantoni, D. et al. Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature. Front. Immunol. 14, 1184362. https:\/\/doi.org\/10.3389\/fimmu.2023.1184362 (2023).","journal-title":"Front. Immunol."},{"key":"46564_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101702","volume":"5","author":"M Schwarzmuller","year":"2024","unstructured":"Schwarzmuller, M. et al. Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines. Cell Rep. Med. 5, 101702. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101702 (2024).","journal-title":"Cell Rep. Med."},{"key":"46564_CR65","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-021-03841-4","volume":"597","author":"V Oberhardt","year":"2021","unstructured":"Oberhardt, V. et al. Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine. Nature 597, 268\u2013273. https:\/\/doi.org\/10.1038\/s41586-021-03841-4 (2021).","journal-title":"Nature"},{"key":"46564_CR66","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1093\/infdis\/jiac229","volume":"227","author":"HR Lapointe","year":"2023","unstructured":"Lapointe, H. R. et al. People with Human Immunodeficiency Virus receiving suppressive antiretroviral therapy show typical antibody durability after dual Coronavirus Disease 2019 vaccination and strong third dose responses. J. Infect. Dis. 227, 838\u2013849. https:\/\/doi.org\/10.1093\/infdis\/jiac229 (2023).","journal-title":"J. Infect. Dis."},{"key":"46564_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-70725-8","volume":"14","author":"WC McMahon","year":"2024","unstructured":"McMahon, W. C. et al. T-cell responses to ancestral SARS-CoV-2 and Omicron variant among unvaccinated pregnant and postpartum women living with and without HIV in South Africa. Sci. Rep. 14, 20348. https:\/\/doi.org\/10.1038\/s41598-024-70725-8 (2024).","journal-title":"Sci. Rep."},{"key":"46564_CR68","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1093\/cid\/ciac408","volume":"75","author":"E Morrocchi","year":"2022","unstructured":"Morrocchi, E. et al. Perinatally Human Immunodeficiency Virus-infected adolescents and young adults demonstrate distinct BNT162b2 messenger RNA coronavirus disease 2019 vaccine immunogenicity. Clin. Infect. Dis. 75, S51\u2013S60. https:\/\/doi.org\/10.1093\/cid\/ciac408 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"46564_CR69","doi-asserted-by":"publisher","unstructured":"Ogbe, A. et al. Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight 7 (2022). https:\/\/doi.org\/10.1172\/jci.insight.157031","DOI":"10.1172\/jci.insight.157031"},{"key":"46564_CR70","doi-asserted-by":"publisher","first-page":"e916","DOI":"10.1093\/cid\/ciab1009","volume":"75","author":"MA Spinelli","year":"2022","unstructured":"Spinelli, M. A. et al. Differences in Post-mRNA vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) concentrations and surrogate virus neutralization test response by Human Immunodeficiency Virus (HIV) status and type of vaccine: A matched case-control observational study. Clin. Infect. Dis. 75, e916\u2013e919. https:\/\/doi.org\/10.1093\/cid\/ciab1009 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"46564_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00452-6","volume":"7","author":"ZL Brumme","year":"2022","unstructured":"Brumme, Z. L. et al. Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. NPJ Vaccines 7, 28. https:\/\/doi.org\/10.1038\/s41541-022-00452-6 (2022).","journal-title":"NPJ Vaccines"},{"key":"46564_CR72","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/QAD.0000000000003161","volume":"36","author":"M Gonzalez de Aledo","year":"2022","unstructured":"Gonzalez de Aledo, M. et al. Safety and Immunogenicity of SARS-CoV-2 vaccines in people with HIV. AIDS 36, 691\u2013695. https:\/\/doi.org\/10.1097\/QAD.0000000000003161 (2022).","journal-title":"AIDS"},{"key":"46564_CR73","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s15010-021-01721-7","volume":"50","author":"S Noe","year":"2022","unstructured":"Noe, S. et al. Humoral response to SARS-CoV-2 vaccines in people living with HIV. Infection 50, 617\u2013623. https:\/\/doi.org\/10.1007\/s15010-021-01721-7 (2022).","journal-title":"Infection"},{"key":"46564_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/v15102004","author":"L Marchitto","year":"2023","unstructured":"Marchitto, L. et al. Humoral responses elicited by SARS-CoV-2 mRNA vaccine in people living with HIV. Viruses https:\/\/doi.org\/10.3390\/v15102004 (2023).","journal-title":"Viruses"},{"key":"46564_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11111664","author":"A Vergori","year":"2023","unstructured":"Vergori, A. et al. SARS-CoV-2 mRNA vaccine response in people living with HIV according to CD4 Count and CD4\/CD8 ratio. Vaccines https:\/\/doi.org\/10.3390\/vaccines11111664 (2023).","journal-title":"Vaccines"},{"key":"46564_CR76","doi-asserted-by":"publisher","first-page":"12448","DOI":"10.1038\/s41598-021-91746-7","volume":"11","author":"D Mannar","year":"2021","unstructured":"Mannar, D., Leopold, K. & Subramaniam, S. Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry. Sci. Rep. 11, 12448. https:\/\/doi.org\/10.1038\/s41598-021-91746-7 (2021).","journal-title":"Sci. Rep."},{"key":"46564_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-2915-7","volume":"18","author":"EO Odhiambo","year":"2019","unstructured":"Odhiambo, E. O. et al. HIV infection drives IgM and IgG3 subclass bias in Plasmodium falciparum-specific and total immunoglobulin concentration in Western Kenya. Malar. J. 18, 297. https:\/\/doi.org\/10.1186\/s12936-019-2915-7 (2019).","journal-title":"Malar. J."},{"key":"46564_CR78","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.158402","author":"DJ Schuster","year":"2022","unstructured":"Schuster, D. J. et al. Lower SARS-CoV-2-specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.158402 (2022).","journal-title":"JCI Insight"},{"key":"46564_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13992-8","volume":"11","author":"U Steffen","year":"2020","unstructured":"Steffen, U. et al. IgA subclasses have different effector functions associated with distinct glycosylation profiles. Nat. Commun. 11, 120. https:\/\/doi.org\/10.1038\/s41467-019-13992-8 (2020).","journal-title":"Nat. Commun."},{"key":"46564_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/cells9122676","author":"LAN Staats","year":"2020","unstructured":"Staats, L. A. N. et al. IgA2 antibodies against SARS-CoV-2 correlate with NET formation and fatal outcome in severely diseased COVID-19 patients. Cells https:\/\/doi.org\/10.3390\/cells9122676 (2020).","journal-title":"Cells"},{"key":"46564_CR81","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41435-022-00179-3","volume":"23","author":"R Lopez-Martinez","year":"2022","unstructured":"Lopez-Martinez, R. et al. IGHG3 hinge length variation was associated with the risk of critical disease and death in a Spanish COVID-19 cohort. Genes Immun. 23, 205\u2013208. https:\/\/doi.org\/10.1038\/s41435-022-00179-3 (2022).","journal-title":"Genes Immun."},{"key":"46564_CR82","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163669","author":"MJ Peluso","year":"2023","unstructured":"Peluso, M. J. et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI163669 (2023).","journal-title":"J. Clin. Invest."},{"key":"46564_CR83","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-011110-130254","volume":"6","author":"S Moir","year":"2011","unstructured":"Moir, S., Chun, T. W. & Fauci, A. S. Pathogenic mechanisms of HIV disease. Annu. Rev. Pathol. 6, 223\u2013248. https:\/\/doi.org\/10.1146\/annurev-pathol-011110-130254 (2011).","journal-title":"Annu. Rev. Pathol."},{"key":"46564_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101442","volume":"5","author":"J Sop","year":"2024","unstructured":"Sop, J. et al. Bivalent mRNA COVID vaccines elicit predominantly cross-reactive CD4(+) T cell clonotypes. Cell Rep. Med. 5, 101442. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101442 (2024).","journal-title":"Cell Rep. Med."},{"key":"46564_CR85","first-page":"130","volume":"9","author":"CI Mboto","year":"2009","unstructured":"Mboto, C. I., Davies-Russell, A., Fielder, M. & Jewell, A. P. CD4+ lymphocyte values and trends in individuals infected with human immunodeficiency virus and\/or co-infected with hepatitis C virus in the Gambia. Afr. Health Sci. 9, 130\u2013136 (2009).","journal-title":"Afr. Health Sci."},{"key":"46564_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1178788","volume":"13","author":"X Li","year":"2023","unstructured":"Li, X. et al. CD4(+) T cell counts and soluble programmed death-1 at baseline correlated with hepatitis B surface antigen decline in HIV\/HBV coinfection during combined antiretroviral therapy. Front. Cell Infect. Microbiol. 13, 1178788. https:\/\/doi.org\/10.3389\/fcimb.2023.1178788 (2023).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"46564_CR87","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/tmi.13082","volume":"23","author":"HL Gronborg","year":"2018","unstructured":"Gronborg, H. L. et al. Prevalence and clinical characteristics of CMV coinfection among HIV infected individuals in Guinea-Bissau: A cross-sectional study. Trop. Med. Int. Health 23, 896\u2013904. https:\/\/doi.org\/10.1111\/tmi.13082 (2018).","journal-title":"Trop. Med. Int. Health"},{"key":"46564_CR88","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3855\/jidc.10035","volume":"12","author":"CMD Silva","year":"2018","unstructured":"Silva, C. M. D. et al. Impact of HBV and HCV coinfection on CD4 cells among HIV-infected patients: A longitudinal retrospective study. J. Infect. Dev. Ctries. 12, 1009\u20131018. https:\/\/doi.org\/10.3855\/jidc.10035 (2018).","journal-title":"J. Infect. Dev. Ctries."},{"key":"46564_CR89","unstructured":"Gruber, D. et al. Louisiana HIV, AIDS, and Early Syphilis Surveillance Quarterly Report 44 (Louisiana Department of Health, 2022)."},{"key":"46564_CR90","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01647-22","volume":"13","author":"KA Bowman","year":"2022","unstructured":"Bowman, K. A. et al. Hybrid immunity shifts the Fc-effector quality of SARS-CoV-2 mRNA vaccine-induced immunity. MBio 13, e0164722. https:\/\/doi.org\/10.1128\/mbio.01647-22 (2022).","journal-title":"MBio"},{"key":"46564_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-26149-z","volume":"15","author":"J Klingler","year":"2025","unstructured":"Klingler, J. et al. Reduced Fc-mediated antibody responses after COVID-19 mRNA vaccination in a cohort of people living with HIV-1. Sci. Rep. 15, 41988. https:\/\/doi.org\/10.1038\/s41598-025-26149-z (2025).","journal-title":"Sci. Rep."},{"key":"46564_CR92","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.cmi.2025.06.007","volume":"31","author":"JL Casado","year":"2025","unstructured":"Casado, J. L. et al. Humoral and cellular immune responses in people living with HIV following successive COVID-19 vaccine booster doses. Clin. Microbiol. Infect. 31, 1855\u20131864. https:\/\/doi.org\/10.1016\/j.cmi.2025.06.007 (2025).","journal-title":"Clin. Microbiol. Infect."},{"key":"46564_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2023.100189","volume":"3","author":"CJ Lauritsen","year":"2024","unstructured":"Lauritsen, C. J. et al. Passive antibody transfer from pregnant women to their fetus are maximized after SARS-CoV-2 vaccination irrespective of prior infection. J. Allergy Clin. Immunol. Glob. 3, 100189. https:\/\/doi.org\/10.1016\/j.jacig.2023.100189 (2024).","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"46564_CR94","doi-asserted-by":"publisher","DOI":"10.1002\/cpmc.108","volume":"58","author":"F Amanat","year":"2020","unstructured":"Amanat, F. et al. An in vitro microneutralization assay for SARS-CoV-2 serology and drug screening. Curr. Protoc. Microbiol. 58, e108. https:\/\/doi.org\/10.1002\/cpmc.108 (2020).","journal-title":"Curr. Protoc. Microbiol."},{"key":"46564_CR95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010828","volume":"18","author":"SN Seifert","year":"2022","unstructured":"Seifert, S. N. et al. An ACE2-dependent Sarbecovirus in Russian bats is resistant to SARS-CoV-2 vaccines. PLoS Pathog. 18, e1010828. https:\/\/doi.org\/10.1371\/journal.ppat.1010828 (2022).","journal-title":"PLoS Pathog."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46564-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46564-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46564-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:03:45Z","timestamp":1781089425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46564-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["46564"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-46564-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This clinical study and all procedures were approved by the Tulane University Biomedical Institutional Review Board and performed according to the relevant guidelines set forth by the Tulane Human Research Protection Office, Federal Wide Assurance #FWA00002055, and study specific protocol 2020\u2013585.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"17872"}}